Aura Biosciences appoints Teresa Bitetti to Board of Directors

Aura Biosciences, Inc.

Teresa Bitetti appointed as Class II director effective March 31, 2025, filling newly created vacancy.
Bitetti is President of Global Oncology at Takeda; also appointed to Compensation Committee.
Received initial stock option for 29,000 shares and RSU for 21,000 shares, vesting over 3 years.
Board size increased from six to seven directors.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Teresa Marie Bitetti

Class II Director

AURA · Aura Biosciences, Inc.

Effective: 2025-03-31
Filed: April 2, 2025, 7:59 PM ET

unanimously appointed Teresa Marie Bitetti, MBA, as a Class II director, effective March 31, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Teresa Marie Bitetti was appointed as Class II Director at Aura Biosciences, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

unanimously appointed Teresa Marie Bitetti, MBA, as a Class II director, effective March 31, 2025

View on SEC.gov

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-048880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.